New drug NTB003 aims to reduce bulging eyes in thyroid disease

NCT ID NCT07462130

Not yet recruiting Disease control Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called NTB003 in 74 people with thyroid eye disease, a condition that can cause bulging eyes and inflammation. Participants receive injections of NTB003 or a placebo every 4 weeks. The study measures whether the drug reduces eye bulging and quiets disease activity. Because it is a Phase 1b/2 trial, the main goals are safety and finding the right dose, so it is too early to know if NTB003 will become a standard treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NTB003 (a drug given by injection under the skin every 4 weeks)
What this could lead to: If successful, this could point toward a new treatment option to reduce eye bulging and inflammation in people with thyroid eye disease.
What could go wrong: This is an early-phase trial (Phase 1b/2) with only 74 participants, so results may not apply to everyone. The drug's safety and effectiveness are still unproven, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID EYE DISEASE

More trials for these conditions

Other studies related to the condition(s) this trial covers.